Latigo collects $150M to get non-opioid data to compete with Vertex in acute pain
Latigo Biotherapeutics thinks it can one-up Vertex Pharmaceuticals' recently approved Journavx, which ignited the non-opioid landscape for treating pain. The Los Angeles-area biotech is testing a similar type of small molecule, called ...
Latigo Biotherapeutics thinks it can one-up Vertex Pharmaceuticals' recently approved Journavx, which ignited the non-opioid landscape for treating pain.
The Los Angeles-area biotech is testing a similar type of small molecule, called ...
